Carfilzomib Use in Multiple Myeloma

Does a reduced dosing frequency of carfilzomib affect outcomes for patients with R/R myeloma?Подробнее

Real world outcomes of RRMM using Kyprolis | Sharlene Dong, MD, MS | EHA 2024Подробнее

Race Oncology hits 12-month high with new multiple myeloma findingsПодробнее

Isatuximab, carfilzomib, lenalidomide, and dexamethasone in multiple myeloma: the SKylaRk trialПодробнее

ASH 2023 Multiple Myeloma Highlights – PERSEUS, IsKia, Bortezomib dosing, KarMMA-3Подробнее

Addressing nephrotoxicity in agents commonly used to treat multiple myelomaПодробнее

Maintenance therapy with carfilzomib, pomalidomide, and dexamethasone (KPd) in high-risk myeloma ptsПодробнее

Once Weekly Selinexor, Carfilzomib and Dexamethasone in Triple Class Refractory Multiple MyelomaПодробнее

Daratumumab, Carfilzomib, Lenalidomide and Dex for HR Smoldering Multiple Myeloma: ASCENT TrialПодробнее

Carfilzomib - Kyprolis In a nutshell.Подробнее

Mechanisms of resistance to carfilzomib in patients with multiple myelomaПодробнее

Selinexor, Carfilzomib, and Dexamethasone in Treating Patients with Relapsed or Refractory MyelomaПодробнее

All About CARVYKTI #myelomaПодробнее

Overview on the use of KRd for myeloma in a real-world settingПодробнее

PROTEOSOME INHIBITORS Mechanism of Action. Pharmacology. Bortezomib, Ixazomib. Myeloma treatment.Подробнее

Clinical Trials for Multiple Myeloma Patients (Selinexor, CAR T Cell) | Donna’s StoryПодробнее

Know Your Myeloma Therapy: Carfilzomib (Kyprolis) with Dr. Harsh ParmarПодробнее

High-dose carfilzomib recaptures response in r/r multiple myelomaПодробнее

Once Weekly Selinexor, Carfilzomib, and Dexamethasone (XKd) in Heavily Pretreated Multiple MyelomaПодробнее

All About Kyprolis (carlfilzomib) #myelomaПодробнее